Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background The multikinase inhibitor dasatinib exerts growth‐inhibitory effects in patients with imatinib‐resistant chronic myeloid leukaemia (CML). In first clinical trials, side effects of dasatinib, 140 mg daily, were reported to be mild and tolerable. Patients and methods We examined the side effect profile in 16 patients with imatinib‐resistant CML who received 140 mg dasatinib daily in our center. Results Dasatinib produced substantial and sometimes severe or even life‐threatening side effects with ≥ 10% body weight loss (6/16 patients), pleural effusions grade II or higher (12/16) and infectious complications (12/16), including atypical infections not seen in imatinib‐treated patients. One patient developed Epstein–Barr‐Virus‐positive mucosal leucoplakia, one died from pneumonia caused by pneumocystis carinii and three patients developed a skin‐cancer. Most events were recorded within the first 2 years of therapy, only skin tumours developed after the second year. In ex vivo experiments performed in dasatinib‐treated patients, transient suppression of IgE‐dependent activation of blood basophils and TcR‐dependent activation of T‐lymphocytes was found. Moreover, in drug‐binding studies, dasatinib was found to bind to several key kinase‐targets of the immune system including Lyn and Btk, in mast cell, basophil, B‐cell and T‐cell lines. Conclusion Dasatinib acts not only anti‐neoplastic in CML but may also act as an immunosuppressive agent when applied at 140 mg daily, and produces frequent pleural effusions and weight loss in advanced CML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Self-citation
Cited by
Bendall, S. C., Simonds, E. F., Qiu, P., Amir, E.-A. D., Krutzik, P. O., Finck, R., Bruggner, R. V., Melamed, R., Trejo, A., Ornatsky, O. I., et al. (2011) · Science · doi:10.1126/science.1198704 · Cited by 2,279
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Steegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., García-Gutiérrez, V, Hochhaus, A., Kim, D.-W., Kim, T. D., Khoury, H. J., Le Coutre, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.104 · Cited by 482
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Valent, P., Hadzijusufovic, E., Schernthaner, G.-H., Wolf, D., Rea, D., & le Coutre, P. (2015) · Blood · doi:10.1182/blood-2014-09-594432 · Cited by 283
Self-citationHost Control of Fungal Infections: Lessons from Basic Studies and Human Cohorts
Lionakis, M. S., & Levitz, S. M. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053318 · Cited by 209
Metadata
- Authors
- Sillaber, C., Herrmann, H., Bennett, K., Rix, U., Baumgartner, C., Böhm, A., Herndlhofer, S., Tschachler, E., Superti‐Furga, G., Jäger, U., & Valent, P.
- Venue
- European Journal of Clinical Investigation
- Publisher
- Wiley
- Published
- 2009-11-09
- Volume
- 39
- Issue
- 12
- Pages
- 1098-1109
- ISSN
- 0014-2972 (ISSN-L)
- 1365-2362
- OpenAlex
- W2152024997
- Cited by
- 106
- References
- 2
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. https://app.cochat.ai/papers/10.1111/j.1365-2362.2009.02206.x
- The paper
- Sillaber, C., Herrmann, H., Bennett, K., Rix, U., Baumgartner, C., Böhm, A., Herndlhofer, S., Tschachler, E., Superti‐Furga, G., Jäger, U., & Valent, P. (2009). Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. European Journal of Clinical Investigation. https://doi.org/10.1111/j.1365-2362.2009.02206.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.